

Infectious Diseases Labs

ID LABS



Prof Anil Koul

Vice President and Head Johnson & Johnson Innovative Medicine



Friday 13th September 2024 2:00 PM to 3:00 PM (SGT)

Venue: Codon A & B, L5 Matrix Building

Challenges in new Drug Discovery for Global Public Health – why translational science matters?

Cosmetic solutions, such as drug repurposing, cannot achieve major innovations in global public health. We require novel and inventive approaches that cater to distinct unmet medical requirements, particularly those geared towards neglected diseases. For example, the discovery of novel drugs, such as Bedaquiline, has changed treatment paradigms for diseases like drug-resistant tuberculosis. Bedaquiline has demonstrated that novel innovations can have a significant impact on patients' lives and improve social and economic outcomes, especially in low and middle-income countries.

Prof Anil Koul is Vice President for research and development in Communicable Diseases unit of Johnson and Johnson. He is member of the board of Janssen Pharmaceutica NV, a subsidiary of J&J in Europe, with fiduciary responsibility. He leads a multi-disciplinary team of scientists, project managers and operational leaders for discovery and early clinical development of new drugs. In addition to his role at J&J, Anil holds a position of Professor of Translation Discovery at the London School of Hygiene and Tropical Medicine, focused on translational medical research.

Anil has 24 years of experience in pharmaceutical drug discovery and early clinical development, as well as leading public-sector institutions. He has a proven track record of successfully advancing projects from the initial stages of drug discovery to human Phase II POC studies. He was responsible for overseeing more than five drug-candidates as they progressed from discovery to early/late clinical phases. He is experienced with small-molecules, biologicals, peptides, and microbiomes platforms, as well as overseeing programs in therapeutic areas such as ID, Neuroscience, and other disease indications.

Hosted by: Prof Laurent Renia

